CY1113138T1 - 10,10-DONUT PROSTANOIC ACID DERIVATIVES AS AGENTS FOR REDUCING INTRODUCTION - Google Patents
10,10-DONUT PROSTANOIC ACID DERIVATIVES AS AGENTS FOR REDUCING INTRODUCTIONInfo
- Publication number
- CY1113138T1 CY1113138T1 CY20121100873T CY121100873T CY1113138T1 CY 1113138 T1 CY1113138 T1 CY 1113138T1 CY 20121100873 T CY20121100873 T CY 20121100873T CY 121100873 T CY121100873 T CY 121100873T CY 1113138 T1 CY1113138 T1 CY 1113138T1
- Authority
- CY
- Cyprus
- Prior art keywords
- donut
- agents
- acid derivatives
- indicates
- glaucoma
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical class CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 title 1
- 208000010412 Glaucoma Diseases 0.000 abstract 2
- 206010030043 Ocular hypertension Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- -1 CONHCH2CH2OH Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει μια μέθοδο θεραπείας οφθαλμικής υπέρτασης ή γλαυκώματος που περιλαμβάνει χορήγηση σε ένα ζώο που έχει οφθαλμική υπέρταση ή γλαύκωμα, θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης που αντιπροσωπεύεται με τον γενικό τύπο (I): όπου η διακεκομμένη γραμμή δεικνύει την παρουσία ή την απουσία ενός δεσμού, η εγχάρακτη σφήνα δεικνύει την α (κάτω) διαμόρφωση και το συμπαγές τρίγωνο δεικνύει την β (άνω) διαμόρφωση, το Β είναι ένας απλός, διπλός ή τριπλός ομοιοπολικός δεσμός, το n είναι 0-6, το Χ είναι CH2, S ή Ο, το Υ είναι οποιοδήποτε φαρμακευτικώς αποδεκτό άλας του CO2H ή CO2R, CONR2, CONHCH2CH2OH, CON(CH2CH2OH)2, CH2OR, P(Ο)(OR)2, CONRSO2R, SONR2 ή τύπου (la), το R είναι Η, C1-6 αλκύλ ή C2-6 αλκενύλ, τα R2 και R3 είναι C1-6 γραμμικό αλκύλ που μπορεί να είναι τα ίδια ή διαφορετικά και μπορεί να συνδέονται μεταξύ τους με τέτοιον τρόπο ώστε να σχηματίζουν δακτύλιο που ενσωματώνει τον άνθρακα προς τον οποίο αυτά συνδέονται κοινώς.The present invention provides a method of treating ocular hypertension or glaucoma comprising administering to an animal having ocular hypertension or glaucoma a therapeutically effective amount of a compound represented by the general formula (I): wherein the dashed line indicates the presence or absence of a bond, the incised wedge indicates the (lower) configuration and the solid triangle indicates the (upper) configuration, B is a single, double or triple covalent bond, n is 0-6, X is CH2, S or O, Y is any any pharmaceutically acceptable salt of CO2H or CO2R, CONR2, CONHCH2CH2OH, CON (CH2CH2OH) 2, CH2OR, P (O) (OR) 2, CONRSO2R, SONR2 or formula (la), R is H, C1-6 alkyl or C2 -6 alkenyl, R2 and R3 are C1-6 linear alkyls that may be the same or different and may be linked together in such a way as to form a ring incorporating the carbon to which they are linked.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/365,369 US6875787B2 (en) | 2003-02-11 | 2003-02-11 | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
| US10/772,720 US20040235958A1 (en) | 2003-02-11 | 2004-02-04 | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
| EP04709028A EP1608309B1 (en) | 2003-02-11 | 2004-02-06 | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113138T1 true CY1113138T1 (en) | 2016-04-13 |
Family
ID=32824631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100873T CY1113138T1 (en) | 2003-02-11 | 2012-09-25 | 10,10-DONUT PROSTANOIC ACID DERIVATIVES AS AGENTS FOR REDUCING INTRODUCTION |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6875787B2 (en) |
| EP (2) | EP2263674B1 (en) |
| CN (3) | CN102050812B (en) |
| AR (1) | AR043138A1 (en) |
| CY (1) | CY1113138T1 (en) |
| DK (2) | DK2263674T3 (en) |
| ES (2) | ES2515217T3 (en) |
| HK (1) | HK1086191A1 (en) |
| IL (1) | IL170052A (en) |
| PT (1) | PT1608309E (en) |
| SI (1) | SI1608309T1 (en) |
| TW (1) | TWI329631B (en) |
| ZA (1) | ZA200505728B (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855226B2 (en) * | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
| US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| BRPI0518242A2 (en) * | 2004-10-26 | 2008-11-11 | Allergan Inc | Therapeutic and release methods of prostaglandin ep4 agonists |
| US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| TWI386208B (en) * | 2005-04-18 | 2013-02-21 | Allergan Inc | Therapeutic substituted cyclopentanones |
| US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| US9308070B2 (en) | 2008-12-15 | 2016-04-12 | Allergan, Inc. | Pliable silk medical device |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| US20110008436A1 (en) | 2009-04-20 | 2011-01-13 | Altman Gregory H | Silk Fibroin Hydrogels and Uses Thereof |
| US20110111031A1 (en) * | 2009-04-20 | 2011-05-12 | Guang-Liang Jiang | Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof |
| US20110052695A1 (en) * | 2009-04-20 | 2011-03-03 | Allergan, Inc. | Drug delivery platforms comprising silk fibroin hydrogels and uses thereof |
| JP2013536183A (en) | 2010-07-30 | 2013-09-19 | アラーガン インコーポレイテッド | Compounds and methods for skin repair |
| WO2012024376A1 (en) * | 2010-08-17 | 2012-02-23 | Allergan, Inc. | Ep2 or ep4 agonists for treating corneal haze |
| US8741281B2 (en) * | 2010-08-19 | 2014-06-03 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| WO2012024072A1 (en) * | 2010-08-19 | 2012-02-23 | Allergan, Inc. | Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition |
| US8697057B2 (en) * | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US20120142684A1 (en) | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
| BR112013021035A2 (en) | 2011-02-17 | 2016-10-11 | Allergan Inc | improved soft tissue replacement compositions and methods |
| EP2678022A2 (en) | 2011-02-23 | 2014-01-01 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| AU2011364973A1 (en) | 2011-04-07 | 2013-11-07 | Allergan, Inc. | Devices, compositions and methods utilizing EP4 and EP2 receptor agonists for preventing, reducing or treating capsular contracture |
| EP2814482A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123275A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123274A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2814510A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| RU2677513C2 (en) | 2014-03-07 | 2019-01-17 | Динаэнергетикс Гмбх Унд Ко. Кг | Device and method for positioning detonator within perforator assembly |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117014A (en) * | 1976-01-09 | 1978-09-26 | Abbott Laboratories | Prostaglandin derivatives |
| JPS59101458A (en) * | 1982-12-01 | 1984-06-12 | Nippon Iyakuhin Kogyo Kk | Novel thiaprostaglandin derivative and its preparation |
| JPS632972A (en) * | 1986-06-20 | 1988-01-07 | Nippon Iyakuhin Kogyo Kk | Novel prostaglandin e1 derivative and production thereof |
| US6187813B1 (en) * | 1990-04-10 | 2001-02-13 | Pharmacia & Upjohn Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| CA2021316C (en) * | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US4994274A (en) * | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| US5028624A (en) | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| AU635294B2 (en) * | 1989-07-27 | 1993-03-18 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| CA2020254A1 (en) * | 1989-07-27 | 1991-01-28 | Ming F. Chan | Intraocular pressure reducing 9, 15-diacyl prostaglandins |
| US5034413A (en) * | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US6034413A (en) * | 1997-02-27 | 2000-03-07 | Texas Instruments Incorporated | High speed biCMOS gate power for power MOSFETs incorporating improved injection immunity |
| DE10057158C1 (en) * | 2000-11-16 | 2002-03-28 | Asglawo Gmbh Stoffe Zum Daemme | Mat used for storing exhaust gas catalyst used for purifying vehicle exhaust gases comprises thread material, and edge protection consisting of temperature-resistant thread along edges of structure |
| US6531504B2 (en) * | 2001-05-17 | 2003-03-11 | Allergan, Inc. | Prostanoic acid derivatives as agents for lowering intraocular pressure |
| CA2466517A1 (en) * | 2001-11-05 | 2003-05-15 | Allergan, Inc. | .omega.-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists |
| US7175476B2 (en) * | 2005-01-11 | 2007-02-13 | Daeun Electronics Co., Ltd. | Crosstalk canceling pattern for high-speed communications and modular jack having the same |
-
2003
- 2003-02-11 US US10/365,369 patent/US6875787B2/en not_active Expired - Lifetime
-
2004
- 2004-02-04 US US10/772,720 patent/US20040235958A1/en not_active Abandoned
- 2004-02-06 CN CN201010530469.8A patent/CN102050812B/en not_active Expired - Fee Related
- 2004-02-06 CN CN2010105303996A patent/CN102050811A/en active Pending
- 2004-02-06 ES ES10178294.4T patent/ES2515217T3/en not_active Expired - Lifetime
- 2004-02-06 EP EP10178294.4A patent/EP2263674B1/en not_active Expired - Lifetime
- 2004-02-06 ES ES04709028T patent/ES2391393T3/en not_active Expired - Lifetime
- 2004-02-06 SI SI200431931T patent/SI1608309T1/en unknown
- 2004-02-06 CN CNA2004800026773A patent/CN1758915A/en active Pending
- 2004-02-06 DK DK10178294.4T patent/DK2263674T3/en active
- 2004-02-06 DK DK04709028.7T patent/DK1608309T3/en active
- 2004-02-06 EP EP14177792.0A patent/EP2803358B1/en not_active Expired - Lifetime
- 2004-02-06 PT PT04709028T patent/PT1608309E/en unknown
- 2004-02-10 AR ARP040100405A patent/AR043138A1/en not_active Application Discontinuation
- 2004-02-11 TW TW093103178A patent/TWI329631B/en not_active IP Right Cessation
-
2005
- 2005-07-18 ZA ZA200505728A patent/ZA200505728B/en unknown
- 2005-08-02 IL IL170052A patent/IL170052A/en active IP Right Grant
-
2006
- 2006-06-02 HK HK06106364.9A patent/HK1086191A1/en not_active IP Right Cessation
-
2012
- 2012-09-25 CY CY20121100873T patent/CY1113138T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1086191A1 (en) | 2006-09-15 |
| DK2263674T3 (en) | 2014-10-27 |
| CN102050812B (en) | 2015-02-18 |
| EP2263674A1 (en) | 2010-12-22 |
| US20040157901A1 (en) | 2004-08-12 |
| EP2263674B1 (en) | 2014-07-23 |
| SI1608309T1 (en) | 2012-11-30 |
| EP2803358A1 (en) | 2014-11-19 |
| DK1608309T3 (en) | 2012-09-03 |
| CN102050811A (en) | 2011-05-11 |
| ES2515217T3 (en) | 2014-10-29 |
| ZA200505728B (en) | 2006-04-26 |
| ES2391393T3 (en) | 2012-11-23 |
| US6875787B2 (en) | 2005-04-05 |
| IL170052A (en) | 2011-10-31 |
| TWI329631B (en) | 2010-09-01 |
| AR043138A1 (en) | 2005-07-20 |
| PT1608309E (en) | 2012-10-18 |
| CN1758915A (en) | 2006-04-12 |
| EP2803358B1 (en) | 2017-05-03 |
| CN102050812A (en) | 2011-05-11 |
| US20040235958A1 (en) | 2004-11-25 |
| TW200512184A (en) | 2005-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113138T1 (en) | 10,10-DONUT PROSTANOIC ACID DERIVATIVES AS AGENTS FOR REDUCING INTRODUCTION | |
| NO2022019I1 (en) | Eribulin or a pharmaceutically acceptable salt thereof - extended SPC | |
| EA200500174A1 (en) | NEW BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | |
| CY1106674T1 (en) | AZADICYCLIC HETERCYCLES AS CANNABINOID RECEPTOR REGULATORS | |
| ATE318267T1 (en) | SOME ALKYLENEDIAMINE SUBSTITUTED HETEROCYCLES | |
| EA200500814A1 (en) | DERIVATIVES OF PYRROPOLYMIDININE | |
| ATE260255T1 (en) | 5-OXO-PYRROLIDINE-2-CARBONIC ACID HYDROXAMIDE DERIVATIVES | |
| PT1029853E (en) | U.S. HETEROAROMATIC BICYCLIC DERIVATIVES AS ANTICANCERIGENE AGENTS | |
| EA200100971A1 (en) | NEW COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | |
| CY1105362T1 (en) | SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DRUGS | |
| LU90562I2 (en) | Imidazoalkanoic acids | |
| EA200500018A1 (en) | BENZONE-CONDENSED HETEROARILAMIDE TYENOPIRIDIN DERIVATIVES USED AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS, INCLUDING THEM, AND THEIR APPLICATION | |
| EA200100553A1 (en) | SUBSTITUTED BICYCLIC DERIVATIVES, USEFUL AS ANTICATIVE AGENTS | |
| BR0310047A (en) | 8-azaprostaglandin analogues as agents for intraocular pressure decrease | |
| EA200400466A1 (en) | DERIVATIVES OF PIPERAZINE WITH ANTAGONISTIC ACTIVITY TO CCR1 RECEPTOR | |
| PT928788E (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS | |
| BE1002102A4 (en) | DERIVATIVES OF QUINOLEINECARBOXYLIC ACID. | |
| PE20070120A1 (en) | DERIVATIVES OF PROSTAGLANDIN | |
| CY1110284T1 (en) | 2-AMINO-4-PYRIDYL-METHYL-THAIZOLINE PRODUCTS AND THEIR USE AS INDUCERS OF INDUCED SYNTHESIS | |
| EE200000472A (en) | Antineoplastic agents | |
| MXPA05008431A (en) | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure. | |
| IT1256320B (en) | HETEROCYCLIC DERIVATIVES | |
| EA200201232A1 (en) | DERIVATIVES OF SULFONAMIDE | |
| ES2111086T3 (en) | AMPHOTERIC TRICYCLIC COMPOUNDS AS ANTIHISTAMINE AND ANTIALLERGIC AGENTS. | |
| EA200500716A1 (en) | NEW CONNECTIONS 2,3-DIHYDRO-4- (1H) -PYRIDON, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |